Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Stock Information for Rafael Holdings Inc. Class B

Loading

Please wait while we load your information from QuoteMedia.